<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01920152</url>
  </required_header>
  <id_info>
    <org_study_id>13-0142</org_study_id>
    <nct_id>NCT01920152</nct_id>
  </id_info>
  <brief_title>Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)</brief_title>
  <official_title>A Randomized Clinical Trial Evaluating Platelet Rich Plasma Versus Hyaluronic-Acid in the Short-term Treatment of Symptomatic OA (Osteoarthritis) of the Hip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the clinical efficacy of intra-articular injections
      of autologous platelet rich plasma (PRP) vs hyaluronic acid (HA) for symptomatic early
      osteoarthritis (OA) of the hip. Secondarily, this study aims to determine the feasibility and
      safety of treating early OA of the hip with HA and PRP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) is a common, painful condition affect adults and causes mobility
      disability in the United States and Europe. Unfortunately, there is no agents available that
      halt OA progression. Analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) have
      suboptimal effectiveness, and there is concern of systemic side effects.

      A large challenge is the development of appropriate and effective therapy in patients with
      OA. Currently, the most suitable route for administering OA therapy appears to be
      intra-articular injections that allow accumulation of critical doses of the drug within the
      damaged area and also reduce the risk of systemic side effects.

      The primary objective of this study is to compare the clinical efficacy of intra-articular
      injections of Platelet Rich Plasma (PRP) vs. Hyaluronic Acid for symptomatic early OA of the
      hip. Secondarily, the study aims to evaluate the safety and feasibility of both medications
      delivered.

      Patients, which meet inclusion criteria, are confirmed eligible, and agree to enroll in the
      study, would be randomized and treated with either three intra-articular PRP injections or
      three intra-articular Hyaluronic Acid injections. If the patient has OA in both hips, they
      will be randomized to receive the same injection in both hips. The Primary investigator will
      be unblinded to the treatment that the subject is randomized to. The PI will only be involved
      in the initial assessment of the patient and the actual injections. All of the follow up
      visits, clinical assessments and outcome scores will be performed by the sub-investigator,
      who will also be the examining physician. The sub-investigator will be blinded to the
      treatment throughout the study. All of the study subjects will be blinded to which treatment
      that they are assigned to.

      Physical exams will be performed to assess range of motion of the hip joint. The difference
      in ranges of motion will be statistically compared at different time points between the two
      groups to determine the difference in improvement between the two compared to baseline.

      The primary efficacy outcome will be defined as the percentage of patients having a 50%
      decrease in the summed score for the WOMAC pain subscale from baseline to week 24. We will
      measure this outcome by applying the WOMAC questionnaire compared with baseline therapy. The
      secondary efficacy outcomes will also include IHOT and Non Arthritic Hip Score.

      An anterior posterior hip radiograph will be performed at 12 months and 24 months to assess
      Kellgren-Classification and compared to baseline.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index)</measure>
    <time_frame>Baseline-24 months follow up</time_frame>
    <description>The primary efficacy outcome will be defined as the percentage of patients having a 50% decrease in the summed score for the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale from baseline to week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in International Hip Outcome Tool (IHOT)</measure>
    <time_frame>Baseline-24 months post inoculation</time_frame>
    <description>Subjective score variation in the International Hip Outcome Tool (IHOT) for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Non Arthritic Hip Score</measure>
    <time_frame>Baseline-24 months</time_frame>
    <description>Subjective score variation on the Non Arthritic Hip Score for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hip Range of motion (ROM)</measure>
    <time_frame>Baseline-24 months</time_frame>
    <description>Score variation on hip range of motion for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FABER TEST</measure>
    <time_frame>Baseline-24 months</time_frame>
    <description>Score variation for FABER test for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anterior Posterior (AP) Pelvis Radiograph/ Kellgren-Lawrence classification.</measure>
    <time_frame>Baseline-24 months</time_frame>
    <description>Score variation on the Kellgren-Lawrence score for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with Adverse Events</measure>
    <time_frame>Week 2-Week 3 and 6-12-18-24 months</time_frame>
    <description>Type, duration and trend of every adverse event for each patient will be reported</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hip Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Autologous PRP Hip Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid Hip Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP</intervention_name>
    <description>Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.</description>
    <arm_group_label>Autologous PRP Hip Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.</description>
    <arm_group_label>Hyaluronic Acid Hip Injection</arm_group_label>
    <other_name>SUPARTZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 35-72 inclusive.

          -  Symptomatic early OA of the hip (Kellgren-Lawrence Grade 1-2-3) documented by x-ray
             taken within the past 6 months.

          -  Women of childbearing potential will be allowed to enroll but must be willing to
             practice one highly effective method of contraception (oral, injectable or implanted
             hormonal methods of contraception, placement of an intrauterine device (IUD) or
             intrauterine system (IUS) condom or occlusive cap with spermicidal
             foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout
             the study.

        Exclusion Criteria:

          -  Patients with polyarticular disease.

          -  Patients with major conditions such as poorly control diabetes, Cardiac Heart Failure
             (CHF), Chronic Obstructive Pulmonary Disease (COPD) or untreated depression

          -  Patients with known blood disorders (Blood disorders (thrombopathy, thrombocytopenia,
             anemia with hemoglobin &lt;9g/dL).

          -  Patients who had intra-articular treatment with steroids within 6 months of
             randomization in this study or received more than 3 previous intra-articular steroid
             injections to the effected hip.

          -  Patients who are pregnant or nursing at the time of consent.

          -  Patients with inflammatory arthritic conditions (e.g. rheumatoid arthritis)

          -  Non-English speaking patients. (Scores used for evaluation have not been validated in
             Spanish)

          -  Patients who had previous hip surgery

          -  Additional disabilities in any of the lower limbs that would interfere with any of the
             clinical assessments.

          -  Chronic use of NSAID (defined as taking NSAID regularly every week for the last 6
             months), steroids or chemotherapy drugs

          -  Treatment with NSAIDs within 2 days prior to randomization in this study

          -  Patients with a BMI over 30. Due to the fact that this study utilize an injection
             technique which may be inaccurate in obese subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Mei-Dan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado, Hip Preservation Center, Orthopedic Department</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mei-Dan O, McConkey MO, Petersen B, McCarty E, Moreira B, Young DA. The anterior approach for a non-image-guided intra-articular hip injection. Arthroscopy. 2013 Jun;29(6):1025-33. doi: 10.1016/j.arthro.2013.02.014. Epub 2013 Apr 13.</citation>
    <PMID>23591381</PMID>
  </reference>
  <reference>
    <citation>Mei-Dan O, Carmont M, Laver L, Mann G, Maffulli N, Nyska M. Intra-articular injections of hyaluronic acid in osteoarthritis of the subtalar joint: a pilot study. J Foot Ankle Surg. 2013 Mar-Apr;52(2):172-6. doi: 10.1053/j.jfas.2012.12.008. Epub 2013 Jan 17.</citation>
    <PMID>23333279</PMID>
  </reference>
  <reference>
    <citation>Mei-Dan O, Carmont MR, Laver L, Mann G, Maffulli N, Nyska M. Platelet-rich plasma or hyaluronate in the management of osteochondral lesions of the talus. Am J Sports Med. 2012 Mar;40(3):534-41. doi: 10.1177/0363546511431238. Epub 2012 Jan 17.</citation>
    <PMID>22253252</PMID>
  </reference>
  <reference>
    <citation>Mei-Dan O, Laver L, Nyska M, Mann G. [Platelet rich plasma--a new biotechnology for treatment of sports injuries]. Harefuah. 2011 May;150(5):453-7, 490. Review. Hebrew.</citation>
    <PMID>21678642</PMID>
  </reference>
  <reference>
    <citation>Mei-Dan O, Lippi G, SÃ¡nchez M, Andia I, Maffulli N. Autologous platelet-rich plasma: a revolution in soft tissue sports injury management? Phys Sportsmed. 2010 Dec;38(4):127-35. doi: 10.3810/psm.2010.12.1835. Review.</citation>
    <PMID>21150152</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip, Chondropenia, Osteoarthritis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

